Effects of olmesartan-based treatment on masked, white-coat, poorly controlled, and well-controlled hypertension:...

Area of Science:

• Cardiology
• Hypertension Management
• Pharmacotherapy

Background:

• Masked hypertension (MH), white-coat hypertension (WCH), and poorly controlled hypertension (PCH) represent distinct challenges in blood pressure management.
• Effective treatment strategies are crucial for mitigating cardiovascular risks associated with these conditions.

Purpose of the Study:

• To evaluate the real-world effectiveness of olmesartan-based treatment on clinic systolic blood pressure (CSBP) and morning home systolic blood pressure (HSBP).
• To assess treatment effects across different hypertensive patient groups: MH, WCH, PCH, and well-controlled hypertension (CH).

Main Methods:

• Analysis of data from the Home Blood Pressure Measurement With Olmesartan Naive Patients to Establish Standard Target Blood Pressure (HONEST) study.
• Inclusion of 21,340 patients categorized by baseline CSBP and morning HSBP levels.
• Assessment of blood pressure changes at 16 weeks of olmesartan-based treatment.

Main Results:

• Olmesartan-based treatment significantly reduced morning HSBP in MH (-12.5 mm Hg) and PCH (-20.3 mm Hg) groups.
• Significant reductions in CSBP were observed in WCH (-15.2 mm Hg) and PCH (-23.1 mm Hg) groups.
• Minimal changes in CSBP and HSBP were noted in the CH group (1.8 mm Hg and 2.0 mm Hg, respectively), indicating no excessive decrease in normal blood pressure.

Conclusions:

• Olmesartan-based therapy is effective in reducing elevated morning HSBP and CSBP in patients with MH and PCH in a real-world setting.
• The treatment demonstrated a favorable safety profile, avoiding excessive blood pressure reduction in patients with well-controlled hypertension.
• These findings support the use of olmesartan-based treatment for tailored hypertension management based on individual patient BP status.